Toggle light / dark theme

Time-Reversal Symmetry and Thermodynamic Forces

Dissipation affects the time asymmetry of fluctuations in systems out of thermodynamic equilibrium. A newly discovered inequality elucidates that connection.

The emergent field of stochastic thermodynamics uses random variables to investigate the dynamics of microscopic systems that operate out of thermodynamic equilibrium, such as active matter and metabolic pathways. Now Naruo Ohga and two colleagues at the University of Tokyo have applied tools from stochastic thermodynamics to uncover a universal law that could find broad applications in the description of active matter, cell metabolism, and other systems whose continuous supply of energy keeps them out of equilibrium [1] (Fig. 1.)

When a thermodynamic system is close to equilibrium, the fluxes of physical quantities, such as energy and electric charge, are linearly proportional to thermodynamic forces, such as temperature gradients and voltage differences. The coefficients connecting the fluxes and forces are symmetric, meaning that the one relating flux A to force B is the same as the one relating flux B to force A. Such symmetries are known as Onsager’s reciprocal relations [2]. At the microscopic level, their origin can be attributed to the time-reversal symmetry of the cross-correlation function between two physical quantities at equilibrium.

Asian Hornet, Cousin Of Infamous Murder Hornet, Found In United States For First Time Ever

O.o!!!


This isn’t unsettling at all.

The infamous murder hornet was discovered in North America for the first time ever in 2019, and the response was understandably fear because of the insect’s name and reputation.

Well, now we have its cousin to worry about, as the Asian hornet (also known as the yellow-legged hornet) has apparently been found in the United States for the first time in history. Oh, and just like the murder hornet, the Asian hornet throws down on honey bees at the dinner table.

Next Generation Cancer Therapy Reveals Major Opportunity

GTB-3550 is the company’s first TriKE® product candidate that was evaluated in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other CD33+ hematopoietic malignancies. Phase 1 clinical trials were shown to be both safe and well-tolerated, as well as proving the molecule’s clinical concept and providing a framework for future product candidates.

GTB-3650 is a second-generation protein developed to treat AML and MDS. It has replaced GTB-3550 and utilizes camelid nanobody technology. GTB3650 has successfully completed pre-clinical trials and is in the good manufacturing process (GMP) stage, which is usually the last developmental milestone before progressing into phase 1 clinical trials.

/* */